[Biologicals in gastroenterology: TNF-blockers].
TNF-blockers represent a well accepted therapeutic option in the treatment of inflammatory bowel disease. Though they are successfully used in many patients, they can also exert severe side effects, such as infectious diseases. Therefore, a careful review of the patient history as well as a continuous evaluation of the patient's state of health is crucial before starting an anti-TNF therapy during the therapeutic treatment. In addition, we review also the possibilities by loss of efficacy of an anti-TNF therapy, such as dose increase or re-induction therapy.
Klinik für Gastroenterologie und Hepatologie, Department für Innere Medizin, Universitätsspital Zürich.
M
M
Scharl
G
G
Rogler
D000068879:Adalimumab; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy*; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D011241:Prednisone